TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

Other analysts also recently issued research reports about the stock. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Wednesday. Stifel Nicolaus set a $12.00 price target on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. HC Wainwright lifted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Finally, Guggenheim set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $10.20.

TriSalus Life Sciences Price Performance

TLSI opened at $3.25 on Friday. TriSalus Life Sciences has a 52-week low of $2.20 and a 52-week high of $7.95. The company has a 50 day moving average of $4.28 and a two-hundred day moving average of $4.36. The company has a market cap of $200.13 million, a P/E ratio of -2.50 and a beta of 0.50. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million. On average, analysts expect that TriSalus Life Sciences will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in TriSalus Life Sciences in the third quarter worth about $68,000. Provenance Wealth Advisors LLC bought a new stake in TriSalus Life Sciences in the third quarter valued at about $94,000. CWA Asset Management Group LLC acquired a new stake in TriSalus Life Sciences during the third quarter valued at approximately $310,000. State Street Corp raised its stake in TriSalus Life Sciences by 86.3% during the second quarter. State Street Corp now owns 610,963 shares of the company’s stock valued at $2,780,000 after buying an additional 282,943 shares in the last quarter. Finally, First Light Asset Management LLC lifted its holdings in TriSalus Life Sciences by 29.3% during the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock worth $29,814,000 after buying an additional 1,485,664 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.